Jiménez-Ochoa Marco Alejandro, Contreras-Serratos María Margarita, González-Bautista Martha Leticia, López-Macías Constantino, Torres-Fierro Anahí, Urbina-Escalante Elizabeth
Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sepúlveda Gutiérrez", Unidad de Trasplante de Médula Ósea. Ciudad de México, México.
Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Especialidades "Dr. Bernardo Sepúlveda Gutiérrez", Unidad de Investigación Médica en Inmunoquímica. Ciudad de México, México.
Rev Med Inst Mex Seguro Soc. 2023 Jan 1;61(Suppl 1):S12-S18.
Hematopoietic stem cell transplants (HSCT) can be performed regardless of the ABO group compatibility between donor and recipient. ABO incompatibility in HSCT is related to pure red cell aplasia (PRCA), or passenger lymphocyte syndrome. The impact of ABO incompatibility on graft-versus-host disease and transplant-related mortality is controversial due to the heterogeneity of procedures carried out in different transplant centers.
To determine the prevalence of ABO incompatibility and its complications in a hematopoietic stem transplant unit.
An observational, retrospective study was carried out in patients undergoing HSCT from January 2014 to January 2020. All trasplant patients were included. Qualitative variables were analyzed using chi-squared test, and Wilcoxon and Student's t tests were used for quantitative variables. A p < 0.05 was considered significant.
124 patients undergoing HSCT were analyzed, out of which 31 had ABO incompatibility, with a punctual prevalence of 24.4%; among them, 54% presented with major incompatibility, 32% minor incompatibility and 13% bidirectional incompatibility. Three cases of PRCA were reported. There were no differences in survival at one year in both groups.
The ABO incompatibility ant its complications were not related to the increase in mortality. Randomized prospective studies are required to define the role of ABO incompatibility in HSCT prognosis.
造血干细胞移植(HSCT)可在供体和受体ABO血型不相容的情况下进行。HSCT中的ABO血型不相容与纯红细胞再生障碍性贫血(PRCA)或过客淋巴细胞综合征有关。由于不同移植中心实施的程序存在异质性,ABO血型不相容对移植物抗宿主病和移植相关死亡率的影响存在争议。
确定造血干细胞移植单元中ABO血型不相容的患病率及其并发症。
对2014年1月至2020年1月接受HSCT的患者进行了一项观察性回顾性研究。纳入所有移植患者。定性变量采用卡方检验分析,定量变量采用Wilcoxon检验和Student's t检验。p<0.05被认为具有统计学意义。
分析了124例接受HSCT的患者,其中31例存在ABO血型不相容,即时患病率为24.4%;其中,54%为主要不相容,32%为次要不相容,13%为双向不相容。报告了3例PRCA病例。两组患者1年生存率无差异。
ABO血型不相容及其并发症与死亡率增加无关。需要进行随机前瞻性研究来确定ABO血型不相容在HSCT预后中的作用。